English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A 69-year-old Caucasian woman presented to her plastic surgeon in 2014 with a several-month history of painful swelling and effusion surrounding her left breast implant. Her medical history was significant for stage II estrogen receptor–positive breast cancer requiring mastectomy and implant placement in 1993, followed by chemotherapy and hormonal treatment with tamoxifen. The patient elected for left implant removal and capsulectomy, as well as prophylactic right-sided mastectomy to treat the recent effusion. Aspiration of the peri-implant fluid revealed atypical CD30-positive lymphocytes suggestive of anaplastic large cell lymphoma. Microscopic examination of the left breast capsule demonstrated similar-appearing ALK-negative, CD30-positive cells that did not penetrate the capsular parenchyma. Deeper sections toward adipose tissue revealed a separate dense infiltrate of small lymphoid cells that were immunoreactive for CD45/LCA and CD20 while negative for CD3, CD5, CD10, CD30, CD43, and CD68, consistent with extranodal marginal zone lymphoma. A similar B-cell population was also identified in a right axillary lymph node excised during the patient’s right-sided prophylactic mastectomy. Subsequent bone marrow biopsy demonstrated 50% to 60% involvement by the marginal zone lymphoma, with no T-cell process identified. The patient was referred to hematology/oncology and was recommended no additional therapy for the anaplastic large cell lymphoma. However, as treatment for the marginal zone lymphoma, she received two doses of rituximab-bendamustine, followed by a 4-week induction course of single-agent rituximab with 2-year maintenance until December 2016. The patient is currently in complete remission. Although B-cell lymphomas have been previously reported in capsules of breast implants, this is the first case to our knowledge in which a B-cell process occurred simultaneously in a patient with breast implant– associated anaplastic large cell lymphoma, stressing differences in the diagnosis and approach to treating these two malignancies.

american journal of clinical pathology

Analysis of Sequential Specimens Shows That Breast Implant–Associated Anaplastic Large Cell Lymphoma Behaves as a Lymphoma Rather Than as a Lymphoproliferative Disorder